Sign in
PDSB Stock Price, Chart, Stats & News
PDS Biotechnology Corporation
Save
PDS Biotechnology Corporation (PDSB) does not currently pay a dividend.
44.58M
Market cap
–
Current P/E
–
Forward P/E
PDSB chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | 3.24% |
ROA | -100.52% |
ROE | -208.95% |
D/E | 1.90x |
Interest coverage ratio | -6.06x |
PDSB valuation
P/E | – |
P/S | – |
P/B | 2.68x |
P/CF | -0.79x |
P/FCF | -0.92x |
P/OCF | -0.79x |
PEG | -0.07x |
EV multiple | -1.23x |
About
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing innovative, multi-functional immunotherapies to combat cancer. Its primary drug candidate, PDS0101 (HPV16), is currently undergoing Phase II clinical trials, positioned as an initial treatment option for recurrent or metastatic head and neck cancer, human papillomavirus (HPV)-associated malignancies, and cervical cancer. The company's developmental pipeline further includes several preclinical product candidates.
Similar securities
Based on sector and market capitalization
Report issue